Ascendis Pharma A (ASND) Receivables (2012 - 2026)

Ascendis Pharma A (ASND) has 15 years of Receivables data on file, last reported at $209.2 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 198.22% year-over-year to $209.2 million; the trailing twelve-month figure through Mar 2026 stood at $209.2 million (up 198.22% YoY), and the FY2025 full-year result was $181.5 million, down 4.54% from the prior year.
• Receivables grew to $209.2 million in Q1 2026, from $181.5 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $209.2 million in Q1 2026 to a low of $4.7 million in Q2 2022.
• A 5-year average of $72.7 million and a median of $44.6 million in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables jumped 8906.72% in 2022 and slipped 3.32% in 2025, its largest moves.
• Tracing ASND's Receivables over 5 years: stood at $25.2 million in 2022, then jumped by 134.3% to $59.1 million in 2023, then surged by 217.38% to $187.7 million in 2024, then declined by 3.32% to $181.5 million in 2025, then increased by 15.26% to $209.2 million in 2026.
• Business Quant data shows ASND's Receivables at $209.2 million in Q1 2026, $181.5 million in Q4 2025, and $157.5 million in Q3 2025.